Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 14,898 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 14,898 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the completion of the transaction, the insider directly owned 85,660 shares of the company’s stock, valued at approximately $4,001,178.60. The trade was a 14.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Mo Qatanani also recently made the following trade(s):

• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total value of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total value of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Trading Down 7.3%

NASDAQ:SRRK traded down $3.47 during mid-day trading on Friday, hitting $44.29. The company had a trading volume of 897,449 shares, compared to its average volume of 1,147,870. The business’s fifty day moving average is $43.59 and its two-hundred day moving average is $37.24. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $48.28. The firm has a market cap of $4.52 billion, a P/E ratio of -14.06 and a beta of 0.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter last year, the company posted ($0.66) earnings per share. As a group, research analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Three Seasons Wealth LLC raised its position in Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after buying an additional 222 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Scholar Rock by 7.9% during the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after purchasing an additional 456 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Scholar Rock by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock worth $130,000 after purchasing an additional 500 shares during the last quarter. California State Teachers Retirement System grew its position in Scholar Rock by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after purchasing an additional 577 shares in the last quarter. Finally, Tema Etfs LLC increased its stake in Scholar Rock by 6.6% in the 4th quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after buying an additional 616 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on SRRK shares. Barclays upped their price objective on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. JPMorgan Chase & Co. raised their price objective on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Bank of America initiated coverage on shares of Scholar Rock in a research note on Thursday, October 9th. They issued a “buy” rating and a $53.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $50.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).